Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s Why

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down prior to trading on Wednesday . The stock had previously closed at $8.34, but opened at $7.93. Telix Pharmaceuticals shares last traded at $7.9150, with a volume of 62,584 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TLX shares. Canaccord Genuity Group raised Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Royal Bank Of Canada started coverage on shares of Telix Pharmaceuticals in a research note on Monday. They set a “hold” rating on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Finally, UBS Group cut their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $9.83 and a 200-day simple moving average of $11.97.

Institutional Trading of Telix Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in Telix Pharmaceuticals during the 3rd quarter worth approximately $1,883,000. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth $3,037,000. Portland Investment Counsel Inc. purchased a new stake in shares of Telix Pharmaceuticals during the 3rd quarter worth $1,225,000. Lazard Asset Management LLC acquired a new position in shares of Telix Pharmaceuticals during the third quarter worth $1,097,000. Finally, Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the second quarter valued at $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.